Contact:
sales@biotechnologyforums.com to feature here

Thread Rating:
  • 0 Vote(s) - 0 Average
  • 1
  • 2
  • 3
  • 4
  • 5
Ranbaxy Laboratories Ltd: Recent News and Job Opportunities
#1
Ranbaxy is a world renowned Pharmaceutical company (serving over 150 Nations), with it's global headquarters in Gurgaon, Haryana (India). With it's diverse portfolio of Generics, Branded Generics, Value-added and Over-the-Counter (OTC) products, Anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs), Vaccines etc, Ranbaxy has a strong hold in the pharmaceutical markets of both the developed and developing nations. Since it's inception in 1961, Ranbaxy has given due consideration to Research and Innovation, enabling it to consistently add depth to it's product pipeline.

Here's a brief overview of the recent updates and job positions at Ranbaxy.
  • Ranbaxy Q2 Results to be declared on August 07, 2013
The Bombay Stock Exchange (BSE) has been informed recently by Ranbaxy that it's Quarter 2 (Q2) results will be declared on August 7, 2013. A meeting of the Board of Directors of the Company will be held on the declared date to shed consideration on Standalone and Consolidated Unaudited Financial Results of Q2, as well as the ended half year (till June 30, 2013).

Click here for the stock report
  • USFDA Sheds Clarification on Ranbaxy's Manufacturing Plants
USFDA told CNBC-TV18 about the lack of any proof on data reliability issues of Ranbaxy's Manufacturing Plants except for 3 plants i.e Paonta Sahib, Batamandi & Dewas. FDA thereby supported the fact that there was no evidence of major current good manufacturing practices (cGMP) violations by Ranbaxy overall. The clarification boosted the shares of Ranbaxy up, leading to a 6.5% gain on July 3, 2013.

Click here for the details
  • Ranbaxy launches Hybrid Business In Brazil in Collaboration with Daiichi Sankyo
In a bid to expand the businesses, Ranbaxy and Daiichi Sankyo have entered into a synergy to launch a hybrid business in Brazil. Ranbaxy will enter the branded generics market of Brazil with this synergism, and for that it will support Daiichi Sankyo Brasil Farmaceutica Ltda, Brazilian subsidiary of Daiichi Sankyo.

Click here for details


Job Opportunities
Following are the recent Job Openings at Ranbaxy, India:
(To apply, Click here)
[Image: ranbaxy.png]

We will keep updating the post.

Thanks for Reading!
Sunil Nagpal
MS(Research) Scholar, IIT Delhi (Alumnus)
Advisor for the Biotech Students portal (BiotechStudents.com)
Computational Researcher in BioSciences at a leading MNC


Suggested Reads:
Top Biotech Companies | Top places to work
Indian Biotech Companies and Job Openings
Aiming a PhD in Top Grad School? | These are the Important Points to Consider
Careers in Biotechnology | A list of various Options
Biotechnology Competitive Exams in India
#2
Award to Ranbaxy Laboratories for its innovation of the anti malarial drug Synriam TM

Date : 16 July 2013

Name of the Award: "Innovation Excellence Platinum Award"

Occasion: ASSOCHAM Innovation Awards 2013

Category: Science and Technology

For the Innovation : New, first of its kind anti malarial drug Synriam TM

About ASSOCHAM Innovation Awards :

ASSOCHAM Innovation Awards serves the motto of identifying innovative organization in India and show cases their excellence in innovation by awarding the organization. So that the organization awarded for excellence will be a trend setter to all the other organizations.

About Synriam TM:

Credit : New anti malarial drug, first of its kind.

Market Entry: World Malarial day 25th April 2012

Purpose: To treat adults infected with Plasmodium falciparum a causative agent of Malaria

Synriam TM: Combination of Arterolane maleate 150 and Piperaquine phosphate 750mg.

Mode of Action:

Arterolane maleate – Acts against the malarial parasite in the blood of the infected person

Piperaquine Phosphate – Acts against the residual malarial parasite and ensures non occurrence of another malarial episode in the treated patient.

Dosage : one tablet per day for 3 days

Price: Rs.130

Business
Targeting the drug markets in Africa, Asia and South America
Ranbaxy is preparing to submit a New drug application proposal to gain the market authorization for the drug Synriam in African regions for the year 2013.

Clinical trials under progress to make this drug available for children in the malarial episode areas in Asia and Africa

Total Number of tablets sold: 2 million

Number of patients cured in India: 7,00,000

Production Feasibility: As this drug is of synthetic origin it can be produced in large scales as and when required without any hurdle.

IP:
Ranbaxy owns the rights for this product and IP for this drug is protected till the year 2022

The drug Synriam TM has also secured Golden Peacock Innovative product / Service Award.

  

Possibly Related Threads...
Thread
Author
  /  
Last Post
Replies: 0
Views: 1,075
04-23-2017, 06:42 PM
Last PostAmmu
Replies: 0
Views: 9,133
07-25-2015, 04:16 AM
Last Postgmshim
Replies: 1
Views: 7,775
03-26-2015, 04:12 PM
Last Postjuston33
Replies: 0
Views: 7,331
02-19-2015, 02:20 PM
Last Postdebram



Users browsing this thread:
1 Guest(s)

Ranbaxy Laboratories Ltd: Recent News and Job Opportunities00